Výsledky vyhledávání - "Joanna Dixon"

Diagnostic Accuracy of Glial Fibrillary Acidic Protein and Ubiquitin Carboxy-Terminal Hydrolase-L1 Serum Concentrations for Differentiating Acute Intracerebral Hemorrhage from Ischemic Stroke

Autor: Kristi G. Bache, Joanna Dixon, Jan Hendrik Schaefer, Christian Foerch, Sebastian Luger, Ferdinand O Bohmann, Karianne Larsen, Steven P Richieri, Maren Ranhoff Hov, Henriette S Jaeger

Publikováno v: Neurocritical Care. 33:39-48

Biomarkers indicative of intracerebral hemorrhage (ICH) may help triage acute stroke patients in the pre-hospital phase. We hypothesized that serum concentration of glial fibrillary acidic protein (GFAP) in combination with ubiquitin carboxy-terminal

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1ea1d2324e3eaf8f209b2b6ad9ae6075
https://doi.org/10.1007/s12028-020-00931-5

Zobrazit plný text záznamu

Diagnostic Accuracy of Glial Fibrillary Acidic Protein and Ubiquitin Carboxy-Terminal Hydrolase-L1 Serum Concentrations for Differentiating Acute Intracerebral Hemorrhage from Ischemic Stroke

Autor: Sebastian, Luger, Henriette S, Jæger, Joanna, Dixon, Ferdinand O, Bohmann, JanHendrik, Schaefer, Steven P, Richieri, Karianne, Larsen, Maren R, Hov, Kristi G, Bache, Christian, Foerch

Publikováno v: Neurocritical care. 33(1)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::570eb49ba82c6e40e8b4d52ceed5658c
https://pubmed.ncbi.nlm.nih.gov/32144632

Zobrazit plný text záznamu

Abstract WP441: Diagnostic Accuracy of Glial Fibrillary Acidic Protein and Ubiquitin Carboxy-Terminal Hydrolase-L1 for Differentiating Acute Intracerebral Hemorrhage From Ischemic Stroke

Autor: Jan H Schaefer, Sebastian Luger, Joanna Dixon, Henriette S Jæger, Christian Foerch, Maren Ranhoff Hov, Ferdinand O Bohmann, Kristi G. Bache

Publikováno v: Stroke. 50

Background: Biomarkers indicative of intracerebral hemorrhage (ICH) may help triage acute stroke patients in the pre-hospital phase. The objective of this study was to investigate whether serum levels of glial fibrillary acidic protein (GFAP) in comb

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::168bda2507720e7ca3f7649f7504c1ef
https://doi.org/10.1161/str.50.suppl_1.wp441

Zobrazit plný text záznamu

Prevention and management of obinutuzumab-associated toxicities: Australian experience

Autor: Joanna Dixon, Alicia Snowden, Ingrid Hayden, Gareth P. Gregory

Publikováno v: International Journal of Nursing Practice. 21:15-27

Patients with chronic lymphocytic leukaemia (CLL) are typically diagnosed at an advanced age and may have multiple co-existing conditions, augmenting the challenges of treating their CLL. Aggressive cytotoxic therapies are often poorly tolerated in t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a80b85034e6a82470c829912b365f70b
https://doi.org/10.1111/ijn.12412

Zobrazit plný text záznamu

A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study)

Autor: John Catalano, Matt Truman, Paula Marlton, Simon McRae, Joanna Dixon, Daniel Thurley, Huyen Tran, Andrew Grigg, Timothy A. Brighton, Maher K. Gandhi

Publikováno v: British Journal of Haematology. 167:243-251

The efficacy of a fixed-dose rituximab schedule was prospectively explored in primary/acute refractory, relapsed or chronic (platelet count >10 × 10(9) /l and ≤50 × 10(9) /l) idiopathic thrombocytopenic purpura (ITP). Patients received two doses

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e90e9b8ed0f3c70849fe9c81fb090580
https://doi.org/10.1111/bjh.13029

Zobrazit plný text záznamu

Prevention and management of obinutuzumab-associated toxicities: Australian experience

Autor: Alicia, Snowden, Ingrid, Hayden, Joanna, Dixon, Gareth, Gregory

Publikováno v: International journal of nursing practice. 21

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::f2d2fcc3c3c55ed252a4e42b62c582b6
https://pubmed.ncbi.nlm.nih.gov/26681665

Zobrazit plný text záznamu

Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer

Autor: Stefania Salvagni, Javier Cortes, Joan Albanell, Joanna Dixon, Karen A. Gelmon, Teresa M Petrella, Pierfranco Conte, Giulia Bianchi, José Baselga, Ana Lluch, Maurizio Scaltriti, V. Servent, Luca Gianni, Pierre Fumoleau, Xavier Pivot, Graham Ross, Shailendra Verma, Tania Szado

Publikováno v: Journal of Clinical Oncology
Journal of Clinical Oncology, 2012, 30 (14), pp.1594-600. ⟨10.1200/JCO.2011.37.4207⟩
Journal of Clinical Oncology, American Society of Clinical Oncology, 2012, 30 (14), pp.1594-600. ⟨10.1200/JCO.2011.37.4207⟩

Purpose The combination of pertuzumab and trastuzumab resulted in a clinical benefit rate (CBR) of 50% in patients with human epidermal growth factor receptor 2 (HER2) –positive breast cancer whose disease progressed during prior trastuzumab-based

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd26e9866e5bfdd2b47bef6bff3929f1
https://pubmed.ncbi.nlm.nih.gov/22393085

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání